Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.49 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20024696 | 0.94 | AHR (0.56) | APPKDM4EAHRCHRNA7CHRNB4 | |
| SCHEMBL15355647 | 0.93 | APP (0.52) | APPKDM4ERECQLAHRCHRNA7 | |
| SCHEMBL19142219 | 0.92 | APP (0.55) | APPKDM4ERECQLAHRCHRNA7 | |
| SCHEMBL13827343 | 0.89 | APP (0.76) | APPMAPT | |
| SCHEMBL3611926 | 0.88 | KDM4E (0.61) | APPKDM4ERECQLMAPT | |
| SCHEMBL12703538 | 0.88 | KDM4E (0.61) | APPKDM4ERECQLMAPT | |
| SCHEMBL22386552 | 0.87 | PPARG (0.50) | APPKDM4ERECQLAHRCHRNA7 | |
| SCHEMBL8845477 | 0.87 | CHRNA7 (0.65) | KDM4ECHRNA7CHRNB4CHRNA3CHRNA10 | |
| SCHEMBL8845489 | 0.87 | CHRNA7 (0.65) | KDM4ECHRNA7CHRNB4CHRNA3CHRNA10 | |
| SCHEMBL10022765 | 0.87 | APP (0.47) | APPKDM4ERECQLAHRCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10982007-B2 | Detection of a posttranslationally modified polypeptide by a bivalent binding agent | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633460-B2 | Binding agent | ROCHE DIAGNOSTIC OPERATIONS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-2659275-B1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2017-09-28 | — | — | US | disclosed |
| EP-2867255-B1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20160194410-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20160194410-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2016-07-07 | — | — | US | disclosed |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012085069-A2 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | FCGR3B, VSIG8, CD47 | APP 3327/4885KDM4E 3240/4885RECQL 4784/4885 |
| US-10982007-B2 | Detection of a posttranslationally modified polypeptide by a bivalent binding agent | PTMS, CD2BP2, PSMA2 | APP 1568/4885KDM4E 3629/4885RECQL 3812/4885 |
| US-20160194410-A1 | BINDING AGENT | SSB, APBA1, SHBG | APP 1770/4885KDM4E 4438/4885RECQL 2028/4885 |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | PTMS, CD2BP2, PSMA2 | APP 1568/4885KDM4E 3629/4885RECQL 3812/4885 |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | PTMS, DNPEP, CD2BP2 | APP 858/4885KDM4E 4191/4885RECQL 4504/4885 |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | APP 2162/4885KDM4E 4465/4885RECQL 1118/4885 |
| US-10633460-B2 | Binding agent | SSB, APBA1, SHBG | APP 1770/4885KDM4E 4438/4885RECQL 2028/4885 |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | APP 615/4885KDM4E 2911/4885RECQL 3733/4885 |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | APP 615/4885KDM4E 2911/4885RECQL 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.